A Post-Market Clinical Evaluation of the Treatment of Tibia Fractures With the T2 Alpha Tibia Nailing System
Launched by STRYKER TRAUMA AND EXTREMITIES · Jul 8, 2019
Trial Information
Current as of May 11, 2025
Completed
Keywords
ClinConnect Summary
The objective of this clinical investigation is to demonstrate the safety and efficacy/performance of the T2 Alpha Tibia Nailing System. Efficacy/performance of the procedure will be measured by an equal or higher (non-inferior) SF-36 Physical Component Summary (PCS) score result of the T2 Alpha Tibia Nailing System compared to the T2 Tibia benchmark literature at 12 months.
In addition, demonstration of bone consolidation in correct alignment will be measured by Investigator assessment by 12 months. Safety of the T2 Alpha Tibia Nailing System will be demonstrated through reporting of devi...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject is a male or non-pregnant female age 18 years or older at the time of surgery;
- • Subject is willing and able to give written informed consent and comply with the requirements of this Clinical Investigation Plan;
- * Subject is intended to be, treated with the Tibial Nail of the T2 Alpha Tibia Nailing System in accordance with the following legally cleared/ approved Indications for Use:
- Indications for Use approved In United States and Canada include:
- • Open and closed tibial fractures
- • Pseudoarthrosis and correction osteotomy
- • Pathologic fractures, impending pathologic fractures and tumor resections
- • Fractures involving osteopenic and osteoporotic bone
- • Nonunions and malunions
- Exclusion Criteria:
- • Subject is currently enrolled in or plans to enroll in any concurrent drug and/or device clinical investigation that, in the opinion of the Investigator, may confound results;
- • Per the Investigator, the subject is in poor general health or undergoing any concurrent disease that would place the subject in excessive risk to surgery (i.e. significant circulatory problems, cardiac disease).
About Stryker Trauma And Extremities
Stryker Trauma and Extremities is a leading medical technology company dedicated to advancing innovative solutions for the treatment of trauma and orthopedic conditions. With a strong focus on research and development, Stryker is committed to improving patient outcomes through cutting-edge products and comprehensive clinical trials. The company leverages its expertise in trauma and extremity surgery to deliver safe, effective, and minimally invasive solutions that enhance surgical efficiency and promote rapid recovery. By collaborating with healthcare professionals and leveraging data-driven insights, Stryker Trauma and Extremities aims to set new standards in the field of musculoskeletal care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Falls Church, Virginia, United States
Cincinnati, Ohio, United States
Sartell, Minnesota, United States
Patients applied
Trial Officials
Rebecca Gibson
Study Director
Stryker Trauma and Extremities
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials